Private Advisor Group LLC Has $17.29 Million Stock Position in Pfizer Inc. $PFE

Private Advisor Group LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 678,416 shares of the biopharmaceutical company’s stock after selling 18,679 shares during the period. Private Advisor Group LLC’s holdings in Pfizer were worth $17,286,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer in the third quarter worth approximately $29,000. Howard Hughes Medical Institute purchased a new position in shares of Pfizer during the second quarter valued at approximately $30,000. Darwin Wealth Management LLC bought a new stake in Pfizer during the second quarter worth $32,000. Evelyn Partners Asset Management Ltd purchased a new stake in Pfizer in the 2nd quarter valued at $33,000. Finally, True Wealth Design LLC lifted its stake in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.2%

PFE opened at $27.12 on Wednesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a market cap of $154.22 billion, a PE ratio of 19.94 and a beta of 0.47. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a 50 day moving average of $26.38 and a 200 day moving average of $25.49.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.63 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date was Friday, January 23rd. Pfizer’s payout ratio is presently 126.47%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PFE. Royal Bank Of Canada began coverage on shares of Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price objective on the stock. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. BMO Capital Markets restated an “outperform” rating and set a $30.00 price target on shares of Pfizer in a report on Monday. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. Finally, Scotiabank began coverage on Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.05.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase‑2 readout for tilrekimig (PF‑07275315) — the study met its primary endpoint (EASI‑75 at Week 16) and Pfizer plans late‑stage testing, which materially strengthens the company’s dermatology pipeline and future growth prospects. Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate-to-Severe Atopic Dermatitis Pfizer’s eczema drug meets main goal in mid-stage trial
• Neutral Sentiment: FDA approved leucovorin for a rare genetic condition but not for autism — important regulatory news for the sector but not directly tied to Pfizer’s marketed products or near‑term revenue. FDA Approves Leucovorin—But Not For Autism
• Neutral Sentiment: Patent activity around tafamidis (a competing transthyretin amyloidosis drug) and related market moves lifted other small caps — the BridgeBio story signals shifting patent dynamics that could influence competitive positioning over time but the impact on Pfizer is uncertain. Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer’s Patent Shake-Up
• Neutral Sentiment: BioNTech cofounders stepping down rattled biotech sentiment broadly; this is sector noise that can increase volatility but does not directly affect Pfizer’s fundamentals. BioNTech Cofounders To Step Down. Stock Crumbles.
• Negative Sentiment: Investor concern over Pfizer’s payout ratio (reported >100%) and a quarterly loss raised the specter of dividend pressure — this remains a key negative risk that can cap upside and prompt selling. Pfizer’s Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?
• Negative Sentiment: Despite the positive eczema data, some reports noted shares dipped earlier — signaling profit‑taking and investor skepticism that new pipeline data will immediately translate to material revenue. That caution can mute sustained rallies. Pfizer shares dip despite positive trial results for skin condition drug

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.